Breakthrough COVID-19 case after full-dose administration of CoronaVac vaccine

Ulhaq, Zulvikar Syambani; Soraya, Gita Vita; Indriana, Kristin

doi:10.1016/j.ijmmb.2021.05.017

Cited by 8 publications

(10 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it is interesting to note that all vaccinated subjects were either asymptomatic or exhibited milder symptoms, except Case number 7, and the symptoms were resolved within 7-14 days, similar to the previous finding. 11 The Ig anti-RBD levels in postinfected individuals were increased (Table 1), but this finding was not observed in Cases 2 and 8, in line with a previous report where patients with symptomatic infection did not respond or had lower antibody levels. 12 In Case number 6, the level of Ig anti-RBD was declined after 3 months and marginally closed to the threshold of positivity, and nearly 7 months later, the subject was reinfected with SARS-CoV-2 (Table 1).…”

supporting

confidence: 88%

The level of Ig anti‐RBD SARS‐CoV‐2 after two doses of CoronaVac vaccine

Ulhaq

Soraya

Indriana

et al. 2021

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

The safety and immunogenicity of the two-dose injections of the CoronaVac vaccine (Sinovac Life Sciences) have been reported in Phase 1 and 2 trials. 1,2 After the approval of CoronaVac by the Indonesian government, the coronavirus disease 2019 (COVID-19) vaccination program was launched in January 2021, with the first administration batch targeted towards healthcare workers. However, published data regarding the humoral immune response after Cor-onaVac vaccination in subjects not included in clinical trials are scarce. Therefore, this report aims to evaluate the effectiveness of two doses of CoronaVac vaccine by investigating the level of total Ig anti-receptor binding domain (RBD) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This is a retrospective study carried out using nonprobability sampling. Subjects were included based on the fulfillment of the following criteria: (1) healthy volunteers; (2) healthcare workers receiving Cor-onaVac vaccine between January and March 2021; (3) has received two doses of CoronaVac (at a 2-week interval [0 and 14 days], with each dose containing inactivated SARS-CoV-2 virus 3 mcg [600 SU] in 0.5 ml); (4) has had a measurement of the Ig anti-RBD quantified by Elecsys Anti-SARS-CoV-2 S (Roche, cut-off value ≥ 0.8 U/ml) after the second dose of CoronaVac vaccine. The Elecsys Anti-SARS-CoV-2 S serology assay is a quantitative electrochemiluminescence immunoassay (ECLIA) utilizing a recombinant protein representing the RBD of the spike antigen and captures predominantly anti-SARS-CoV-2 IgG. 3,4 This study was approved by the Faculty of Medicine and Health Science, Maulana Malik Ibrahim State Islamic University of Malang ethics committee (Ref. No. 023/EC/KEPK-FKIK/2021), and informed consent was obtained from all subjects.The Ig anti-RBD measurement time was varied, ranging from 7 to 49 days after the second dose of the CoronaVac vaccine. Subjects were hence grouped according to the time of Ig anti-RBD measurement. The Ig anti-RBD level between groups was statistically analyzed either by one-way analysis of variance (ANOVA) or paired/ unpaired t-test using SPSS version 25 with a significance threshold of p < 0.05, and all figures were generated using the Graphpad PRISM.Initially, a total of 131 subjects, consisting of 59 male (45%) and 72 female (55%) healthcare workers (mean age overall, 35.

show abstract

supporting

confidence: 88%

The level of Ig anti‐RBD SARS‐CoV‐2 after two doses of CoronaVac vaccine

Ulhaq

Soraya

Indriana

et al. 2021

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Reinfection with SARS-CoV-2 is a possibility in both vaccinated and unvaccinated individuals, because vaccines to the virus may not translate to total immunity [199]. Recently breakthrough infections were reported following mRNA vaccination in healthy subjects [200,201], despite evidence of effective immune response among the breakthrough subjects [202]. Another study reported that eight symptomatic SARS-CoV-2 infections occurred in fully vaccinated healthcare workers (incidence rate 4.7 per 100,000 person-days adjusted) [203].…”

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2 Reinfection Is a New Challenge for the Effectiveness of Global Vaccination Campaign: A Systematic Review of Cases Reported in Literature

Muzio

Ambosino

Muzio

et al. 2021

IJERPH

View full text Add to dashboard Cite

Reinfection with SARS-CoV-2 seems to be a rare phenomenon. The objective of this study is to carry out a systematic search of literature on the SARS-CoV-2 reinfection in order to understand the success of the global vaccine campaigns. A systematic search was performed. Inclusion criteria included a positive RT-PCR test of more than 90 days after the initial test and the confirmed recovery or a positive RT-PCR test of more than 45 days after the initial test that is accompanied by compatible symptoms or epidemiological exposure, naturally after the confirmed recovery. Only 117 articles were included in the final review with 260 confirmed cases. The severity of the reinfection episode was more severe in 92/260 (35.3%) with death only in 14 cases. The observation that many reinfection cases were less severe than initial cases is interesting because it may suggest partial protection from disease. Another interesting line of data is the detection of different clades or lineages by genome sequencing between initial infection and reinfection in 52/260 cases (20%). The findings are useful and contribute towards the role of vaccination in response to the COVID-19 infections. Due to the reinfection cases with SARS-CoV-2, it is evident that the level of immunity is not 100% for all individuals. These data highlight how it is necessary to continue to observe all the prescriptions recently indicated in the literature in order to avoid new contagion for all people after healing from COVID-19 or becoming asymptomatic positive.

show abstract

“…Recently, in this scenario, healthy vaccinated subjects report positive tests and symptoms of SARS-CoV-2 infection [ 7 , 8 ], despite confirmation of adequate immune response among these patients [ 9 ].…”

Section: Discussionmentioning

confidence: 99%

Symptomatic SARS-CoV-2 Infection with Ageusia after Two mRNA Vaccine Doses

Caponio

Lipsi

Fortunato

et al. 2022

IJERPH

View full text Add to dashboard Cite

To raise awareness about preventive measures in COVID-19 pandemic, even though fully vaccinated. Although recent trials showed high efficacy of vaccines in preventing symptomatic infections, there are some individuals experiencing symptomatic SARS-CoV-2 infection. In this case report, a fully vaccinated young dental practitioner experienced symptomatic SARS-CoV-2 infection 55 days postvaccination with BNT162b2 Pfizer vaccine with evident ageusia. Diagnostic swabs were performed and used for viral genome sequencing. The patient fully recovered 15 days after diagnosis. Loss of smell and taste, together with nasal congestion were the main reported symptoms. The use of personal protective equipment prevented spread of infection in patients and co-workers. With the increase of people being fully vaccinated, it is still necessary to follow infection preventive protocols by correctly applying personal protective equipment. Although high efficacy has been proved, some individuals may still be vulnerable to symptomatic infection and new guidelines and markers should be adopted and investigated to find out patients for whom vaccination may not determine full immunization.

show abstract

Breakthrough COVID-19 case after full-dose administration of CoronaVac vaccine

Cited by 8 publications

References 3 publications

The level of Ig anti‐RBD SARS‐CoV‐2 after two doses of CoronaVac vaccine

The level of Ig anti‐RBD SARS‐CoV‐2 after two doses of CoronaVac vaccine

SARS-CoV-2 Reinfection Is a New Challenge for the Effectiveness of Global Vaccination Campaign: A Systematic Review of Cases Reported in Literature

Symptomatic SARS-CoV-2 Infection with Ageusia after Two mRNA Vaccine Doses

Contact Info

Product

Resources

About